<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1684">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05139238</url>
  </required_header>
  <id_info>
    <org_study_id>AAAT5925</org_study_id>
    <nct_id>NCT05139238</nct_id>
  </id_info>
  <brief_title>Postpartum Hypertension Study</brief_title>
  <official_title>Oral Nifedipine Versus Intravenous Labetalol for Postpartum (PP) Hypertensive Emergency: A Randomized Clinical Trial (RCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess which blood pressure medication (intravenous labetalol&#xD;
      or oral nifedipine) works better in treating severely elevated blood pressure in women who&#xD;
      have just delivered a baby.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypertensive emergencies cause significant maternal morbidity and mortality in the postpartum&#xD;
      period. In order to reduced these risks, the recommendation is to treat women with severe&#xD;
      range blood pressure with either intravenous labetalol or oral nifedipine; it is unclear&#xD;
      which medication is superior. The objective of this study is to prospectively enroll women&#xD;
      who have hypertensive emergencies in the postpartum period; women will be randomized in a 1:1&#xD;
      fashion and treated with one of the two antihypertensives to see which one works better.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Time to Initial Blood Pressure Control (minutes)</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>The primary outcome will be time (minutes) interval required to achieve the therapeutic BP goal of &lt;160 mmHg systolic and &lt;110 mmHg diastolic.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average Number of Recurrence of Severe Blood Pressure</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>The number of times a patient has recurrence of severe hypertensive necessitating treatment with an antihypertensive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Participants Who Need for Second Antihypertensive Agent</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>The need to use a second (alternative) antihypertensive medication.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Postpartum Pregnancy-Induced Hypertension</condition>
  <condition>Postpartum Preeclampsia</condition>
  <condition>Pregnancy-Induced Hypertension in Postpartum</condition>
  <condition>Hypertensive Emergency</condition>
  <arm_group>
    <arm_group_label>Oral Nifedipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral nifedipine: Once diagnosis of hypertensive emergency is confirmed on repeat blood pressure, patients randomized to oral nifedipine will receive 10mg initially, with repeated doses of 20mg every 20min, for up to a maximum of 5 doses or until the therapeutic blood pressure goal of &lt;160 systolic and &lt;105 diastolic is achieved. If the therapeutic goal is not achieved after 5 doses, crossover to the alternative study medication will occur.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous labetalol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous Labetalol: Patients randomized to IV labetalol will receive 20mg initially, followed by escalating doses of 40mg, 80mg, 80mg, then 80mg every 20 minutes until the therapeutic goal is achieved, for a maximum of 5 doses. If the therapeutic goal is not achieved after 5 doses, crossover to the alternative study medication will occur.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Labetalol</intervention_name>
    <description>Intravenous labetalol, a short acting ant-hypertensive</description>
    <arm_group_label>Intravenous labetalol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine</intervention_name>
    <description>Oral nifedipine, a short acting ant-hypertensive</description>
    <arm_group_label>Oral Nifedipine</arm_group_label>
    <other_name>Oral Procardia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Patients admitted to labor and delivery (L&amp;D) with blood pressure (BP) in severe&#xD;
             range, defined as a systolic ≥160 mm Hg and/or diastolic ≥110 mm Hg&#xD;
&#xD;
          -  Postpartum, immediately to 6 weeks postpartum&#xD;
&#xD;
          -  With a prior diagnosis of chronic hypertension (not on medication) or hypertensive&#xD;
             disorder of pregnancy&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  They may not have previously had exposure to either study medication within the&#xD;
             previous 24-hour period.&#xD;
&#xD;
          -  Patients with a known atrial-ventricular heart block or moderate to severe bronchial&#xD;
             asthma will be excluded, or other contraindication to receiving either study&#xD;
             medication&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Whitney A. Booker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Whitney A. Booker, MD</last_name>
    <phone>212-305-7334</phone>
    <email>wb2322@cumc.columbia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Whitney A. Booker, MD</last_name>
      <phone>212-305-7334</phone>
      <email>wb2322@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Whitney A. Booker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 18, 2021</study_first_submitted>
  <study_first_submitted_qc>November 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Whitney Booker</investigator_full_name>
    <investigator_title>Assistant Professor of Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Hypertensive Emergency</keyword>
  <keyword>Postpartum</keyword>
  <keyword>Preeclampsia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Hypertension, Pregnancy-Induced</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Malignant</mesh_term>
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Labetalol</mesh_term>
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

